July 14 (Reuters) - Tylenol maker Kenvue's ( KVUE ) CEO

and board member Thibaut Mongon had stepped down, it said on

Monday and named company director Kirk Perry as interim chief

executive.

The company, which was spun off from Johnson & Johnson ( JNJ )

in 2023, has been under pressure from activist investors

to boost performance, particularly in its skin-health and beauty

unit, which includes brands such as Neutrogena and Aveeno.

"The Board's strategic review is underway, and we are

considering a broad range of potential alternatives, including

ways to simplify the company's portfolio and how it operates,"

said board chair Larry Merlo.

Perry has previously spent 23 years with Procter & Gamble ( PG )

. He most recently served as president and CEO of Circana,

a global provider of technology, data and predictive analytics

for the consumer, retail and media sectors.